DCGI nod to Akums Perampanel Oral Suspension to treat epilepsy seizures

According to a report by the World Health Organisation (WHO) around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. An estimated 5 million people are diagnosed with epilepsy every year. India has more than 10 million patients with epilepsy, i.e., 20% out 50 million worldwide.

"We are excited about the approval of Perampanel Oral Suspension, as it provides another treatment option for patients with epilepsy who may have difficulty swallowing tablets or prefer liquids," said Mr. Sanjeev Jain, Jt. Managing Director, Akums Drugs & Pharmaceuticals. "The development of this new formulation underscores Akums' unwavering commitment to advancing epilepsy care and making significant contributions to address the diversified needs of epilepsy patients and their families."

"The successful management of partial-onset seizures remains a significant challenge for many epilepsy patients and the incidence of uncontrolled seizures remains alarmingly high, despite the availability of existing treatments," explained Mr. Sandeep Jain, Jt. Managing Director, Akums Drugs & Pharmaceuticals. "Perampanel represents an important new option for the treatment of partial-onset epilepsy, and it holds the potential to play a key role in improving seizure management, particularly in poorly controlled adults and adolescents."

The newly approved Perampanel Oral Suspension formulation is now available in 100mL bottles, with a strength of 0.5mg/mL. The packaging includes a convenient oral dosing applicator ensuring accurate dosage administration and enhancing patient compliance.

Read also: Include more government sites in Febuxostat ER tablet trial: CDSCO Panel Nod tells Akums Drugs